Peptide and protein drugs: The study of their metabolism and catabolism by mass spectrometry

被引:60
作者
Katsila, Theodora [1 ]
Siskos, Alexandros P. [1 ]
Tamvakopoulos, Constantin [1 ]
机构
[1] Biomed Res Fdn, Acad Athens, Div Pharmacol Pharmacotechnol, GR-11527 Athens, Greece
关键词
metabolism; metabolite; catabolism; stability; degradation; peptide; protein drug; biopharmaceuticals; mass spectrometry; structure elucidation; quantification; LC-MS/MS; PERFORMANCE LIQUID-CHROMATOGRAPHY; IN-VITRO METABOLISM; FUSION INHIBITOR ENFUVIRTIDE; PARATHYROID-HORMONE; HUMAN PLASMA; CYCLOSPORINE-A; RAT-BRAIN; ELECTROSPRAY-IONIZATION; THERAPEUTIC PEPTIDES; SALMON-CALCITONIN;
D O I
10.1002/mas.20340
中图分类号
O433 [光谱学];
学科分类号
0703 ; 070302 ;
摘要
Peptide and protein drugs have evolved in recent years into mainstream therapeutics, representing a significant portion of the pharmaceutical market. Peptides and proteins exhibit highly diverse structures, broad biological activities as hormones, neurotransmitters, structural proteins, metabolic modulators and therefore have a significant role as both therapeutics and biomarkers. Understanding the metabolism of synthetic or biotechnologically derived peptide and protein drugs is critical for pharmaceutical development as metabolism has a significant impact on drug efficacy and safety. Although the same principles of pharmacokinetics and metabolism of small molecule drugs apply to peptide and protein drugs, there are few notable differences. Moreover, the study of peptide and protein drug metabolism is a rather complicated process which requires sophisticated analytical techniques, and mass spectrometry based approaches have provided the capabilities for efficient and reliable quantification, characterization, and metabolite identification. This review article will focus on the current use of mass spectrometry for the study of the metabolism of peptide and protein drugs. (C) 2011 Wiley Periodicals, Inc., Mass Spec Rev 31:110133, 2012
引用
收藏
页码:110 / 133
页数:24
相关论文
共 155 条
  • [1] Mass spectrometry-based proteomics
    Aebersold, R
    Mann, M
    [J]. NATURE, 2003, 422 (6928) : 198 - 207
  • [2] Cyclosporin: revisions in monitoring guidelines and review of current analytical methods
    Andrews, D
    Cramb, R
    [J]. ANNALS OF CLINICAL BIOCHEMISTRY, 2002, 39 : 424 - 435
  • [3] [Anonymous], 2008, MED DEV BIOT SURV
  • [4] [Anonymous], 2009, IMS HLTH GLOB REP
  • [5] Ghrelin and its therapeutic potential for cachectic patients
    Ashitani, Jun-ichi
    Matsumoto, Nobuhiro
    Nakazato, Masamitsu
    [J]. PEPTIDES, 2009, 30 (10) : 1951 - 1956
  • [6] Simultaneous quantification of acylated and desacylated ghrelin in biological fluids
    Aydin, Suleyman
    Karatas, Fikret
    Geckil, Hikmet
    [J]. BIOMEDICAL CHROMATOGRAPHY, 2008, 22 (12) : 1354 - 1359
  • [7] Monitoring the neuropeptide metabolites by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry
    Babu, CVS
    Lho, DS
    Yoo, YS
    [J]. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2006, 40 (01) : 136 - 141
  • [8] Electron capture dissociation mass spectrometry in characterization of peptides and proteins
    Bakhtiar, Ray
    Guan, Ziqiang
    [J]. BIOTECHNOLOGY LETTERS, 2006, 28 (14) : 1047 - 1059
  • [9] Balani SK, 2000, DRUG METAB DISPOS, V28, P1274
  • [10] Glucagon-Like Peptide (GLP)-1(9-36)Amide-Mediated Cytoprotection Is Blocked by Exendin(9-39) Yet Does Not Require the Known GLP-1 Receptor
    Ban, Kiwon
    Kim, Kyoung-Han
    Cho, Chan-Kyung
    Sauve, Meghan
    Diamandis, Eleftherios P.
    Backx, Peter H.
    Drucker, Daniel J.
    Husain, Mansoor
    [J]. ENDOCRINOLOGY, 2010, 151 (04) : 1520 - 1531